No Data
The submission of the Pre-NDA application for Alectinib tablets (TY-9591).
This drug is expected to become the world's first third-generation EGFR-TKI targeting patients with brain metastases from non-small cell lung cancer (NSCLC).
Tongyuan Kang Pharmaceutical (02410) TY-9591 selected for ASCO, a breakthrough achieved by local Innovative Drugs companies.
The latest research results of TY-9591, a core product of TYK MEDICINES-B (02410), were selected for the report at the 2025 American Society of Clinical Oncology (ASCO) conference.
Tongyuan Kang Pharmaceutical announced its 2024 performance, further releasing the commercial potential of key products.
Hong Kong, Shanghai, and Huzhou Changxing, March 29, 2025 /PR Newswire/ -- Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd. (Stock code: 2410.HK) announced its 2024 performance on March 27, 2025. The group's total revenue is 0.107 million yuan, mainly due to the increase in R&D service income. During the reporting period, the loss was 0.387 billion yuan, with R&D costs at approximately 0.235 billion yuan, narrowing by 5.5% year-on-year, which shows that the company is paying more attention to efficiency and cost control in R&D investment. By the end of 2024, the group's cash and bank balance was 0.46 billion yuan, compared to
TYK MEDICINES-B (02410.HK) reported an annual loss of 0.388 billion yuan with cash reserves of 0.46 billion yuan.
On March 27, Glonghui reported that TYK MEDICINES-B (02410.HK) announced its annual performance, with the group's revenue increasing from 0 yuan for the year ending December 31, 2023, to 0.107 million yuan for the year ending December 31, 2024, mainly due to an increase in revenue from research and development services. The overall gross profit increased from 0 yuan for the year ending December 31, 2023, to 14,000 yuan for the year ending December 31, 2024, with a gross margin of 13.1%. The loss during the reporting period was from the year ending December 31, 2023.
TYK MEDICINES-B (02410): Ding Zhao resigns as a non-executive Director.
TYK MEDICINES-B (02410) announced that Dr. Ding Zhao has tendered his resignation as a non-executive Director of the company, effective from 2025...
TYK MEDICINES-B (02410) announced its 2024 performance, with research and development costs of approximately 0.235 billion yuan, a year-on-year decrease of 5.5%.
TYK MEDICINES-B (02410) announced its 2024 performance, with revenue of 0.107 million yuan and R&D costs of approximately 2.3...
